This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Past Earnings Performance

Past criteria checks 0/6

Key information

14.39%

Earnings growth rate

16.29%

EPS growth rate

Pharmaceuticals Industry Growth	12.39%
Revenue growth rate	-3.94%
Return on equity	n/a
Net Margin	-126.20%
Last Earnings Update	30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Endo International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:ENDPQ N Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	2,552	-3,221	832	154
30 Jun 22	2,783	-2,552	881	148
31 Mar 22	2,928	-681	870	147
31 Dec 21	2,993	-569	841	147
30 Sep 21	2,964	129	767	147
30 Jun 21	2,827	109	687	150
31 Mar 21	2,801	137	688	151
31 Dec 20	2,903	247	671	154
30 Sep 20	2,908	-102	661	125
30 Jun 20	3,002	-75	667	133
31 Mar 20	3,014	-190	648	129
31 Dec 19	2,914	-361	632	131
30 Sep 19	2,936	-418	639	122
30 Jun 19	2,952	-522	635	125
31 Mar 19	2,967	-477	630	181
31 Dec 18	2,947	-962	646	186
30 Sep 18	2,929	-968	640	209
30 Jun 18	2,971	-921	612	209
31 Mar 18	3,132	-1,565	620	168
31 Dec 17	3,469	-1,233	615	172
30 Sep 17	3,942	-4,294	666	170
30 Jun 17	4,039	-4,386	717	175
31 Mar 17	4,084	-3,300	754	185
31 Dec 16	4,010	-3,224	771	183
30 Sep 16	3,842	553	802	181
30 Jun 16	3,704	-59	760	158
31 Mar 16	3,518	-539	721	126

Quality Earnings: ENDPQ N is currently unprofitable.

Growing Profit Margin: ENDPQ N is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ENDPQ N is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.

Accelerating Growth: Unable to compare ENDPQ N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENDPQ N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).

Return on Equity

High ROE: ENDPQ N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/02 08:56
End of Day Share Price	2023/02/28 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Endo Inc. is covered by 45 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Gary Nachman	BMO Capital Markets Equity Research
Sumant Satchidanand Kulkarni	BofA Global Research